logo-loader
viewe-Therapeutics plc

First day for new e-Therapeutics boss

Dr Raymond Barlow arrives from Amgen, where he held a senior role

rsz_shutterstock_178464512.jpg
New face around the table

It is the first day in the new job for e-Therapeutics PLC’s (LON:ETX) new chief executive, who formally took up the role Thursday.

Dr Raymond Barlow, former executive director of corporate development at Amgen, based in Switzerland, said his near-term aim was “to ensure that our resources are appropriately focused on activities that are of the greatest commercial potential”.

"e-Therapeutics is at the forefront of a new wave of science and has created a unique, computational-based drug discovery platform,” he added.

WATCH: New e-therapeutics boss "excited about the future"...

“This platform uses a range of truly cutting-edge technologies, including artificial intelligence.

"I am convinced of the value in the platform and our differentiated approach to drug discovery, which should allow us and potential partners to more efficiently discover more effective drug treatments.”

The 48-year-old will take over day to day running of the company from Iain Ross, who is currently executive chairman and fills the role vacated by Professor Malcolm Young, who stepped down last summer.

His previous responsibilities have included scientific, business and corporate roles with AstraZeneca, Crucell and Johnson & Johnson.

Quick facts: e-Therapeutics plc

Price: 3.2 GBX

AIM:ETX
Market: AIM
Market Cap: £8.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

4 weeks ago

Holding(s) in Company

on 10/29/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Half-year Report

on 10/07/2019

Holding(s) in Company

on 09/17/2019

2 min read